+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non‒small-cell lung cancer or lung metastases



Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non‒small-cell lung cancer or lung metastases



International Journal of Radiation Oncology, Biology, Physics 81(3): 856-862



To investigate the ability of helical tomotherapy (HT) to spare critical organs immediately adjacent to the tumor target in stereotactic body radiation therapy (SBRT) for centrally located lung lesions. HT SBRT plans for 10 patients with centrally located lesions or lesions immediately adjacent to a critical structure were generated. A total of 70 Gy in 10 fractions was prescribed to the planning target volume (PTV) to satisfy a target volume coverage of ≥95% PTV receiving 70 Gy and an established set of dose constraints for the organs at risk (OARs). Quality assurance (QA) of the HT plans was performed with both ion chamber and film measurements. The PTV coverage criteria was met with 95% of the PTV receiving 70.68 ± 0.33 Gy for all cases even though the OARs immediately adjacent to the PTV ranged from 0.38 to 0.85 cm away. The mean lung dose (MLD), and V(20) were 7.15 ± 1.44 Gy, and 11.93 ± 3.24 % for the total lung, respectively. The dose parameters of MLD, V(5), V(10), and V(20) for the contralateral lung were significantly lower than those for the ipsilateral lung (p < 0.05). An average dose fall off from the PTV periphery to the edge of the immediately adjacent OAR was 47.6% over an average distance of 4.87 mm. Comparison of calculated and measured doses with the ion chamber showed an average of 1.85% point dose error, whereas an average mean gamma and the area with a gamma larger than 1 of 0.20 and 0.94% were observed, respectively. HT allows the sparing of critical structures immediately adjacent to the tumor target, thus making SBRT for these centrally located lesions feasible.

(PDF emailed within 0-6 h: $19.90)

Accession: 053220686

Download citation: RISBibTeXText

PMID: 21255942

DOI: 10.1016/j.ijrobp.2010.11.051


Related references

Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry. Radiation Oncology 10: 113, 2016

The potential role of respiratory motion management and image guidance in the reduction of severe toxicities following stereotactic ablative radiation therapy for patients with centrally located early stage non-small cell lung cancer or lung metastases. Frontiers in Oncology 4: 151, 2014

Dosimetric selection for helical tomotherapy based stereotactic ablative radiotherapy for early-stage non-small cell lung cancer or lung metastases. Plos One 7(4): E35809, 2012

Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics 72(4): 967-971, 2008

Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1). International Journal of Clinical Oncology 22(5): 849-856, 2017

Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics 80(4): 1015-1022, 2011

Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone". International Journal of Radiation Oncology, Biology, Physics 88(5): 1120-1128, 2014

Analysis of dose distribution and risk of pneumonitis in stereotactic body radiation therapy for centrally located lung tumors: a comparison of robotic radiosurgery, helical tomotherapy and volumetric modulated arc therapy. Technology in Cancer Research and Treatment 14(1): 49-60, 2015

Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer: in regards to Register et al. Int J Radiat Oncol Biol Phys 2011;80:1015-1022. International Journal of Radiation Oncology, Biology, Physics 82(1): 492; Author Reply 492, 2012

Stereotactic body radiotherapy for centrally located stage I non-small cell lung cancer. Translational Lung Cancer Research 8(1): 58-69, 2019

Stereotactic Body Radiation Therapy (SBRT) For Centrally Located Primary and Recurrent Non-Small Cell Lung Cancer: Analysis of Toxicity and Local Control. International Journal of Radiation Oncology*biology*physics 93(3): E418-E419, 2015

Dosimetric comparison of helical tomotherapy and conventional Linac-based X-knife stereotactic body radiation therapy for primary lung cancer or pulmonary metastases. Journal of Thoracic Disease 10(2): 999-1006, 2018

Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned. Journal of Thoracic Oncology 10(4): 577-585, 2015

Role of Stereotactic Body Radiation Therapy in Early Stage Small Cell Lung Cancer in the Era of Lung Cancer Screening: A Systematic Review. American Journal of Clinical Oncology 2018, 2018

Primary Study Endpoint Analysis for NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology*biology*physics 94(1): 5-6, 2016